Literature DB >> 2654168

The serology of delta hepatitis and the detection of IgM anti-HD by EIA using serum derived delta antigen.

A G Shattock1, M Morris, K Kinane, C Fagan.   

Abstract

A sensitive and specific capture assay for IgM antibody to hepatitis D virus (HDV) was developed employing serum-derived delta antigen (HDAg). In a retrospective and prospective study of an outbreak of hepatitis B (HB), 135 hepatitis B surface antigen (HBsAg) positive drug-abusers with acute hepatitis and 18 HBsAg carriers, attending various hospitals and clinics in Dublin, were found to be infected with HDV. Serological follow-up was available from 24 of those with acute hepatitis allowing a comparison of the duration and level of IgM anti-HD with the more commonly used markers, HDAg and anti-delta (anti-HD), and an assessment of the usefulness of each. HDV and HB serology was grossly altered by human immunodeficiency virus (HIV) in two patients, with severe clinical manifestation in one. All 135 patients with HDV co-infection had delta antigenaemia. In co-infections with optimum sampling times, the mean duration of delta antigenaemia was 21 days. IgM anti-HD was always found between HDAg and sero-conversion to anti-delta and was the only 'window' marker present in five cases. The mean duration of IgM anti-HD was four weeks (optimum at 2.8 weeks) and was of moderate or low titre and occurred simultaneously with HDAg in 78%. In HDV-infected HBsAg carriers, high-titre IgM anti-HD (greater than 1/10,000) persisted for the duration of the study and is a useful indicator of chronic HDV infection. IgM anti-HD was not found in 202 random blood donors nor in 205 patients with non-B hepatitis or other disorders.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2654168     DOI: 10.1016/0166-0934(89)90156-0

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  5 in total

1.  Evaluation of commercial enzyme immunoassays for detection of hepatitis delta antigen and anti-hepatitis delta virus (HDV) and immunoglobulin M anti-HDV antibodies.

Authors:  A G Shattock; M C Morris
Journal:  J Clin Microbiol       Date:  1991-09       Impact factor: 5.948

2.  Viral superinfection in previously unrecognized chronic carriers of hepatitis B virus with superimposed acute fulminant versus nonfulminant hepatitis.

Authors:  C M Chu; C T Yeh; Y F Liaw
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

3.  Estimation of the secondary attack rate for delta hepatitis coinfection among injection drug users.

Authors:  C Poulin; T Gyorkos; L Joseph
Journal:  Can J Infect Dis       Date:  1993-01

Review 4.  Delta hepatitis: molecular biology and clinical and epidemiological features.

Authors:  L B Polish; M Gallagher; H A Fields; S C Hadler
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

5.  Hepatitis delta virus infection in Northern Ireland 1970-1989.

Authors:  R A Curran; H J O'Neill; J H Connolly
Journal:  Ulster Med J       Date:  1991-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.